TARGeted Intraoperative radioTherapy as a tumour bed Boost (TARGIT-B): To compare targeted intra-operative radiotherapy boost with conventional external beam radiotherapy boost after lumpectomy for breast cancer in women with a high risk of local recurrence

Submission date 08/10/2012	Recruitment status No longer recruiting	[X] Prospectively registered		
		[X] Protocol		
Registration date	Overall study status Completed	[] Statistical analysis plan		
10/10/2012		[_] Results		
Last Edited 01/11/2024	Condition category Cancer	Individual participant data		
		[X] Record updated in last year		

Plain English summary of protocol

https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-comparing-a-boostof-radiotherapy-given-during-surgery-and-standard-radiotherapy-after-surgery-for-early-breastcancer-targit-b

Study website

https://targit.org.uk

Contact information

Type(s) Principal Investigator

Contact name Dr Jayant Vaidya

Contact details

Clinical Trials Group, UCL Medical School Centre for Clinical Science and Technology Clerkenwell Building, Archway Campus Highgate Hill London United Kingdom N19 5LW jayant.vaidya@ucl.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number NCT01792726

Secondary identifying numbers HTA 0/104/07, TARGIT Boost

Study information

Scientific Title

TARGIT-B: An international randomised controlled trial to compare targeted intra-operative radiotherapy boost with conventional external beam radiotherapy boost after lumpectomy for breast cancer in women with a high risk of local recurrence

Acronym

TARGIT-B

Study objectives

A pragmatic multi-centre randomised clinical trial to test whether TARGeted Intraoperative radioTherapy as a tumour bed Boost (TARGIT-B) is superior in terms of local relapse within the treated breast compared with standard postoperative external beam radiotherapy boost in women undergoing breast-conserving therapy who have a higher risk of local recurrence.

More details can be found at http://www.hta.ac.uk/project/2946.asp

Study protocol can be found at: http://www.hta.ac.uk/protocols/201001040007.pdf

Ethics approval required Old ethics approval format

Ethics approval(s)

Approved 31/01/2013, REC - Hampshire B (Formally NRES Committee South Central Portsmouth, Bristol HRA Centre, Level 3, Block B, Whitefriars, Lewins Mead, Bristol, BS1 2NT, UK; +44 (0)207 104 8045; nrescommittee.southcentral-hampshireb@nhs.net), REC ref: 12/SC/0731(transferred from 13/LO/0083)

Study design Pragmatic multi-centre randomized clinical trial

Primary study design Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s) Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Early breast cancer

Interventions

Current interventions as of 09/05/2024:

Eligible patients are those with a higher risk (8% at 5 years) of local recurrence after breastconserving surgery. After giving consent patients are randomised to either TARGIT Boost or external beam radiotherapy (EBRT) Boost. All patients will receive whole breast EBRT. They may receive any other adjuvant treatments as deemed necessary. The protocol recommends that patients be followed at 6 monthly intervals for five years and then annually for at least 10 years.

Experimental arm (TARGIT boost):

A tumour bed boost in the form of a single fraction of radiotherapy given intra-operatively and targeted to the tissues at the highest risk of local recurrence.

Control arm (external beam boost): Standard post-operative external beam radiotherapy boost.

Previous interventions:

Eligible patients are those with a higher risk (8% at 5 years) of local recurrence after breastconserving surgery. After giving consent patients are randomised to either TARGIT Boost or external beam radiotherapy (EBRT) Boost. All patients will receive whole breast EBRT. They may receive any other adjuvant treatments as deemed necessary. The protocol recommends that patients be followed at 6 monthly intervals for five years and then annually.

Experimental arm (TARGIT boost):

A tumour bed boost in the form of a single fraction of radiotherapy given intra-operatively and targeted to the tissues at the highest risk of local recurrence.

Control arm (external beam boost): Standard post-operative external beam radiotherapy boost.

Intervention Type

Other

Phase Not Applicable

Primary outcome measure

Local recurrence

Secondary outcome measures

Site of relapse within the breast
 Relapse-free survival and overall survival
 Local toxicity/morbidity

3. Local toxicity/morbidity

Overall study start date

01/03/2013

Completion date

31/10/2024

Eligibility

Key inclusion criteria

Patients diagnosed with breast cancer and suitable for conserving surgery and radiotherapy, with a cytological or histological confirmation of carcinoma can be included in the study once written informed consent is obtained. All patients should be available for regular follow-up (according to local policies) for at least ten years.

At least one of these criteria must be satisfied:

1. Less than 46 years of age

2. More than 45 years of age, but with one of the following poor prognostic factors:

- 2.1. Lymphovascular invasion
- 2.2. Gross nodal involvement (not micrometastasis)

2.3. More than one tumour in the breast but still suitable for breast-conserving surgery through a single specimen

3. More than 45 years of age, but with at least two of the following poor prognostic factors

- 3.1. ER-negative
- 3.2. Grade 3 histology
- 3.3. Positive margins at first excision

4. Those patients with large tumours which have responded to neo-adjuvant chemo- or hormone therapy in an attempt to shrink the tumour and are suitable for breast-conserving surgery as a result

5. Lobular carcinoma or Extensive Intraductal Component (EIC)

6. A combination of high-risk factors are present (as predefined in the policy document) that give a high risk of local recurrence

Participant type(s)

Patient

Age group

Adult

Sex

Female

Target number of participants 1796

Total final enrolment 1684

Key exclusion criteria

1. Bilateral breast cancer at the time of diagnosis

 Patients with any severe concomitant disease that may limit their life expectancy
 Previous history of malignant disease does not preclude entry if the expectation of relapsefree survival at 10 years is 90% or greater (e.g., non-melanoma skin cancer, CIN etc)
 No more than 30 days can have elapsed between last breast cancer surgery (not axillary) and randomisation for patients in the post-pathology stratification unless part of a specific clinical trial that addresses the question of timing or tumour bed can be reliably identified, e.g. by ultrasound

Date of first enrolment 01/03/2013

Date of final enrolment

14/06/2023

Locations

Countries of recruitment

Australia

Canada

Denmark

England

France

Germany

Italy

Norway

Poland

Switzerland

United Kingdom

United States of America

Study participating centre Clinical Trials Group, UCL Medical School London United Kingdom N19 5LW

Sponsor information

Organisation University College London (UK)

Sponsor details JRO, 1st Floor, Maple House 149 Tottenham Court Road London England United Kingdom W1T 7DN alka.mistry@uclh.nhs.uk

Sponsor type University/education

ROR https://ror.org/02jx3x895

Funder(s)

Funder type Government

Funder Name

National Institute for Health Research Health Technology Assessment Programme - HTA (UK) ref: 10/104/07

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type Government organisation

Funding Body Subtype National government

Location

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal.

Intention to publish date

30/04/2026

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication.

IPD sharing plan summary

Other

Study outputs

Output type	Details version V7.0	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Protocol file</u>		15/11/2019	11/09/2020	No	No
HRA research summary			28/06/2023	No	No